Contact
Please use this form to send email to PR contact of this press release:
Apellis Pharmaceuticals Announces 18-Month Results of Phase 2 Study (FILLY) of APL-2 in Geographic Atrophy
TO:
Please use this form to send email to PR contact of this press release:
Apellis Pharmaceuticals Announces 18-Month Results of Phase 2 Study (FILLY) of APL-2 in Geographic Atrophy
TO: